Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
Comparative effectiveness research (CER) has assumed an increasing role in drug coverage and, in some cases, pricing decisions in Europe, as decision-makers seek to obtain better value for money. This issue brief comparatively examines the use of CER across six countries--Denmark, England, France, Germany, the Netherlands, and Sweden. With CER gaining traction in the United States, these international experiences offer insights and potential lessons. Investing in CER can help address the current gap in publicly available, credible, up-to-date, and scientifically based comparative information on the effectiveness of drugs and other health interventions. This information can be used to base coverage and pricing decisions on evidence of value, thereby facilitating access to and public and private investment in the most beneficial new drugs and technologies. In turn, use of CER creates incentives for more efficient, high-quality health care and encourages development of innovative products that offer measurable value to patients.
Sorenson
Corinna
C
LSE Health, London School of Economics and Political Science, England. c.sorenson@lse.ac.uk
D057186:Comparative Effectiveness Research / Q000191:economics / Q000706:statistics & numerical data*; D017047:Cost Sharing; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D003661:Decision Support Techniques; D016527:Drug Costs; D005060:Europe; D006801:Humans; D033181:Information Dissemination; D019458:Insurance Coverage / Q000191:economics*; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D019057:Quality-Adjusted Life Years; D014481:United States